Candriam SCA’s Arcturus Therapeutics ARCT Stock Holding History

Candriam SCA’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-29,401	Closed	-$649K	–	729
2023 Q1	$649K	Buy	+29,401	New	+$527K	﹤0.01%	741
2021 Q2	–	Sell	-53,633	Closed	-$2.23M	–	895
2021 Q1	$2.23M	Hold	53,633	–	–	0.02%	507
2020 Q4	$2.33M	Sell	53,633 -26,087	-33%	-$1.77M	0.02%	519
2020 Q3	$3.42M	Hold	79,720	–	–	0.03%	413
2020 Q2	$3.73M	Buy	+79,720	New	+$2.75M	0.04%	395

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Candriam SCA's ARCT Position: Q2 2023 in Review

Candriam SCA sold out of Arcturus Therapeutics (ARCT) in Q2 2023, closing a stake of 29,401 shares — an estimated $649K sold.

Candriam SCA first reported a position in ARCT in Q2 2020 and held it in 5 quarters. The position peaked at $3.73M in Q2 2020. 143 funds tracked by Wall St. Rank hold ARCT as of Q2 2023.

Candriam SCA reported no remaining Arcturus Therapeutics position as of Q2 2023 after selling out during the quarter.
Candriam SCA sold 29,401 Arcturus Therapeutics shares in Q2 2023, an estimated $649K.
Candriam SCA first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 5 quarters.
Candriam SCA's Arcturus Therapeutics position peaked at $3.73M in Q2 2020.
143 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2023.

Based on Candriam SCA's 13F filing for Q2 2023, filed 8 Aug 2023.